Literature DB >> 7627386

Ranitidine reduces postoperative interleukin-6 induced C-reactive protein synthesis.

L A Rasmussen1, H J Nielsen, S Sørensen, C Sørensen, R Rasmussen, S Sørensen, F Moesgaard, J Larsen.   

Abstract

BACKGROUND: The mechanism of post-traumatic immunosuppression is still not known in detail. However, histamine released during trauma and major surgery may play a significant role in the process. Previously, we showed that the histamine-2 receptor antagonist (H2RA), ranitidine, reduced trauma-induced suppression of certain immunological parameters. STUDY
DESIGN: The effect of perioperative ranitidine on postoperative change in plasma interleukin-6 (IL-6) and serum C-reactive protein (CRP) levels was assessed in 23 women undergoing elective abdominal hysterectomy. The patients were randomized to receive intravenous ranitidine, 100 mg twice a day from skin incision, for two days, followed by oral ranitidine, 150 mg twice a day, for a further three days, or no ranitidine. Interleukin-6 and CRP were analyzed in plasma and serum, respectively, drawn preoperatively and six, 24, 48, and 120 hours after skin incision.
RESULTS: Routine blood analyses, clinical data (except age), duration of surgery, anesthesia, antibiotic prophylaxis, blood loss, and perioperative blood transfusion were similar in the two groups. Interleukin-6 levels were significantly increased in all patients and without difference between the ranitidine-treated and non-ranitidine-treated patients after six, 24, and 48 hours compared to preoperative levels, respectively. C-reactive protein levels were also significantly increased in all patients after 24, 48, and 120 hours, respectively; however, at 48 hours, CRP was significantly reduced in ranitidine-treated patients compared with non-ranitidine-treated patients (p = 0.02).
CONCLUSIONS: These results suggest that histamine-2 receptor activation mechanisms may not be involved in postoperative IL-6 synthesis. However, the reduced CRP level in ranitidine-treated patients suggests that H2RAs modulate IL-6 signal transduction in hepatic cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7627386

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  7 in total

1.  Influence of major surgery on the mannan-binding lectin pathway of innate immunity.

Authors:  H Ytting; I J Christensen; L Basse; J Lykke; S Thiel; J C Jensenius; H J Nielsen
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Increased bone fracture prevalence in postmenopausal women suffering from pollen-allergy.

Authors:  Viktoria Ferencz; Szilvia Meszaros; Emoke Csupor; Edit Toth; Katalin Bors; Andras Falus; Csaba Horvath
Journal:  Osteoporos Int       Date:  2006-01-24       Impact factor: 4.507

Review 3.  Acid-Suppressive Therapy and Risk of Infections: Pros and Cons.

Authors:  Leon Fisher; Alexander Fisher
Journal:  Clin Drug Investig       Date:  2017-07       Impact factor: 2.859

Review 4.  The role of C-reactive protein as a prognostic indicator in advanced cancer.

Authors:  Fade Aziz Mahmoud; Nilo I Rivera
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 5.  Surgical trauma: hyperinflammation versus immunosuppression?

Authors:  Michael D Menger; Brigitte Vollmar
Journal:  Langenbecks Arch Surg       Date:  2004-05-28       Impact factor: 3.445

6.  Acute phase response in patients undergoing lumbar spinal surgery: modulation by perioperative treatment with naproxen and famotidine.

Authors:  M Muñoz; J J García-Vallejo; J M Sempere; R Romero; E Olalla; C Sebastián
Journal:  Eur Spine J       Date:  2003-11-21       Impact factor: 3.134

7.  Preoperatively elevated serum inflammatory markers increase the risk of periprosthetic joint infection following total knee arthroplasty in patients with osteoarthritis.

Authors:  Chi Xu; Heng Guo; Pengfei Qu; Jun Fu; Feng-Chih Kuo; Ji-Ying Chen
Journal:  Ther Clin Risk Manag       Date:  2018-09-17       Impact factor: 2.423

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.